| |
Patients with grade 0-I aGVHD (n=31) |
Patients with grade II-IV aGVHD (n=19) |
P value |
| Male/Female, n/n |
19/12 |
10/9 |
0.547 |
| Age, year (mean ± std) |
8.2 ± 4.0 |
8.5 ± 4.0 |
0.841 |
| Primary diseases, n (%) |
|
|
0.139 |
| ALL |
9 (29.0) |
9 (47.4) |
|
| AML |
14 (45.2) |
5 (26.3) |
|
| CML |
2 (6.4) |
1 (5.3) |
|
| MDS |
0 (0.0) |
3 (15.8) |
|
| JMML |
4 (12.9) |
1( 5.3) |
|
| NHL |
1 (3.2) |
0 |
|
| LCH |
1 (3.2) |
0 |
|
| HSC donor, n (%) |
|
|
0.404 |
| MSD |
10 (41.9) |
2 (10.5) |
|
| MMRD |
4 (12.9) |
4 (21.1) |
|
| MUD |
17 (54.8) |
13 (68.4) |
|
| Stem cell source, n (%) |
|
|
0.836 |
| BM |
3 (9.7) |
3 (10.5) |
|
| PBSC |
27 (87.1) |
15 (84.2) |
|
| CB |
1 (3.2) |
1 (5.3) |
|
| GVHD prophylaxis, n (%) n(%)n(%) prophylaxis,n(%) |
|
|
0.693 |
| CsA+MTX |
27 (87.1) |
15 (78.9) |
|
| CsA+MTX+MMF |
4 (12.9) |
4 (21.1) |
|
|
